Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group
about
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastomaEnhancing Cancer Immunotherapy Via Activation of Innate ImmunityInterleukin-7 and interleukin-15 for cancerAnti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastomaToxicity of upfront ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysisPhase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.New aspects of neuroblastoma treatment: ASPHO 2011 symposium reviewMonoclonal antibodies: versatile platforms for cancer immunotherapy.The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.Synthetic lethal screen identifies NF-κB as a target for combination therapy with topotecan for patients with neuroblastomaAnti-GD2 Strategy in the Treatment of NeuroblastomaEngineering anti-GD2 monoclonal antibodies for cancer immunotherapy.Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy.Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors.Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting.Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study.Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody.Comparison of GD2 binding capture ELISA assays for anti-GD2-antibodies using GD2-coated plates and a GD2-expressing cell-based ELISANeutrophils induced licensing of natural killer cellsComparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma.Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor.Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid.Promising therapeutic targets in neuroblastomaHumanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo.Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment.Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy.Dinutuximab and PanobinostatEthical issues for control-arm patients after revelation of benefits of experimental therapy: a framework modeled in neuroblastomaRESEARCH ADVANCES IN NEUROBLASTOMA IMMUNOTHERAPY.Immunology and immunotherapy of neuroblastomaCurrent and Potential Uses of Immunocytokines as Cancer Immunotherapy.High-risk neuroblastoma: a therapy in evolution.Anti-GD2 antibody therapy for GD2-expressing tumors.p53 family: Therapeutic targets in neuroblastoma.Pharmacotherapy of neuroblastoma.Radioimmunotherapy of solid tumors: searching for the right target.Treatment of high-risk neuroblastoma with anti-GD2 antibodies.Targeted therapy in pediatric and adolescent oncology.Development of treatment strategies for advanced neuroblastoma.
P2860
Q24602657-0E41AF38-16CA-463E-8BD8-3E3E346A9285Q26796313-CE783CB0-1A97-44E9-B42E-7A0071550691Q26830709-9DEED01E-D6FE-44B0-9F63-D71300E148B0Q33408675-91AC88A1-0489-4D3E-8111-0AA88E41C1F1Q33409568-F3184890-2251-47E3-AAD1-023692D39152Q33597441-80807B12-7659-49D7-BA7B-8D41DEE9E322Q33922797-694310BB-7233-48A3-BDC2-88B1421235B9Q34111693-EED4E46E-4560-4C2E-918B-F0DD68BAD1B6Q34186886-AB7775C8-8B2A-48F3-9448-142B9FB2CD2AQ34205125-9FBEFE3F-4E4C-4274-8639-8DAE366ED5E3Q34243887-551ED9F4-78C7-4D81-9A58-BD53A4D6FBE8Q34389202-3EE98439-0630-4E93-B112-EAF483CAE306Q34488726-8E1E9A27-F87A-4429-B708-7C967B4CCC5FQ34541113-E098B3B8-95AE-4B36-9FD0-9161220A36E9Q34589401-136011E8-1F05-4283-9348-817D3BB9E911Q34683623-10BA4774-9474-4467-9A93-947A958BF994Q34877582-B87960AC-BFF2-43C5-BE3C-31FA2DE874F9Q35077759-130AF97B-11D0-4934-B361-AE1FD14F9A45Q35381031-1957E9EA-0DDD-4E48-B933-815D4836B6AAQ35568172-B861C924-B109-4D94-A8BD-2F0C128F4F98Q35587509-1A22445B-CC05-4E5A-BEA9-9013422875D7Q35721147-B3EB57AF-27A9-4F6A-9FE9-2D0DE2BD2BF6Q35752673-D1734EFF-B034-4DD8-B805-41D4DD415B62Q36055313-504EB047-1409-4067-94A6-02291F110CB2Q36057459-863B9E10-1ABC-4994-9C51-62D258ECCCF7Q36455017-44A1822A-B28A-4ADE-BF32-CF563EA55FE3Q36564275-4ECC3448-1172-42CC-A196-E4DF5970E6B5Q36572408-335F595A-9265-44EC-9E21-8F69D8D555BBQ36589638-F74B7526-B160-4883-BD52-472B9BE6F91BQ36776358-2CE89B90-3B3B-47BC-BE8B-A2D72E35A936Q36856798-67C72F43-6B06-46CA-A3C1-62C6E947AA1EQ37637949-C6EBACCB-4759-4197-AC35-CBB69A7DB056Q37642871-79A00090-FBC7-4220-866C-33C06C1F1538Q37702283-7FB474DE-84FA-4F98-B24F-EF4A23AA5A0FQ37707387-DC648A62-2A29-43CC-AAA5-5EC2BF21B27FQ37735199-12DF594E-5F20-43FC-921E-61403B6E1A8BQ37804904-A9997038-5E83-4645-976F-26117B0E041DQ37820755-8179057C-E474-41F3-A664-C70A0F9172FCQ37869437-A8038080-6C59-45D5-828A-01F4FBCB1A68Q38010377-8631F6F4-33E1-4FEA-A55D-A28CDAF824B7
P2860
Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase I study of ch14.18 with ...... the Children's Oncology Group
@en
Phase I study of ch14.18 with ...... the Children's Oncology Group.
@nl
type
label
Phase I study of ch14.18 with ...... the Children's Oncology Group
@en
Phase I study of ch14.18 with ...... the Children's Oncology Group.
@nl
prefLabel
Phase I study of ch14.18 with ...... the Children's Oncology Group
@en
Phase I study of ch14.18 with ...... the Children's Oncology Group.
@nl
P2093
P2860
P921
P356
P1476
Phase I study of ch14.18 with ...... the Children's Oncology Group
@en
P2093
Adam Sternberg
Andrew L Gilman
Gregory H Reaman
Jacquelyn A Hank
Katherine K Matthay
M Fevzi Ozkaynak
Mark Krailo
Paul M Sondel
Robert Seeger
P2860
P356
10.1200/JCO.2006.10.3564
P407
P50
P577
2008-12-01T00:00:00Z